All In Biotech

Drug Trial Radar · NCT06523231

Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

Safety and Immunogenicity of a Second Generation Shigella Bioconjugate Vaccine: a Phase II Randomized, Controlled, and Blinded Study in 9-month-old Infants

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

110

Actual

Start

Apr 7, 2025

Primary completion

Aug 27, 2025

Study completion Jan 22, 2026

Sponsor

Lead sponsor
LimmaTech Biologics AGIndustry
Sponsor type
Industry
Collaborators
Kenya Medical Research Institute
First posted
Jul 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 8 months, up to 10 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study, the second-generation tetravalent bioconjugate candidate vaccine Shigella4V2 will be tested to confirm data on its safety and immunogenicity in infants and to identify the best dose of Shigella4V2 in 9-month-old infants.

Conditions

  • Shigellosis

Interventions

  • Shigella4V2Biological

    Adjuvanted Shigella4V2 administrated at 2 different doses: low and high.

  • MenACWYBiological

    Control vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety - Solicited Local and Systemic Adverse Events (AEs)Time frame: During 7 days following each vaccination
  2. Safety - Unsolicited Adverse Events (AEs)Time frame: During 28 days following each vaccination
  3. Safety - Serious Adverse Events (SAEs)Time frame: Throughout the study, up to 9 months
  4. Immunology - change in serum immunoglobulin G (IgG)Time frame: From first vaccination until 1 month following the second vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • KEMRI - Center for Global Health Research

    Kisumu, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.